15 Results for "

breast tumour cells

" in MedChemExpress (MCE) Product Catalog:
Products (15)

15 Results for "breast tumour cells" in MCE Product Catalog:

Cat. No.: HY-B0237
CAS No.: 125-84-8
Synonyms: DL-Aminoglutethimide
Target:  

Cytochrome P450

Aminoglutethimide (DL-Aminoglutethimide) is an orally active anticonvulsant with various endocrine-related side effects. Aminoglutethimide blocks multiple steroid hormone synthesis pathways by inhibiting several cytochrome P-450-dependent hydroxylases, such as aromatase, cholesterol side-chain cleavage enzyme, 11-hydroxylase, and 18-hydroxylase, with IC50 values of 0.3, 3.5, 120, and 20 μM, respectively. Aminoglutethimide reduces cortisol levels. Aminoglutethimide can be used in research on Cushing's syndrome, breast cancer, and other conditions .
loading...
    loading...
Cat. No.: HY-156991
CAS No.: 1407166-70-4
Synonyms: NODA-GA-NHS ester
Research Areas:  

Cancer

NODAGA-NHS (NODA-GA-NHS ester) is the activated ester form of the NODAGA chelator. NODAGA-NHS conjugates with Trastuzumab (HY-P9907) to form NODAGA-Trastuzumab, a conjugate that can chelate 64Cu for the preparation of radiotracers. NODAGA-NHS covalently binds to the amino group of lactosamine derivatives to form radiotracer precursors. [ 64Cu]NODAGA-trastuzumab enables PET imaging of tumors expressing HER2. NODAGA-NHS is used in studies of HER2-positive breast cancer and ovarian adenocarcinoma .
loading...
    loading...
Cat. No.: HY-108016
CAS No.: 1182-87-2
Purity:  99.32%
Synonyms: Encordin
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .
loading...
    loading...
Cat. No.: HY-P2760
CAS No.: 9001-47-2
Synonyms: GLS
Research Areas:  

Cancer

Glutaminase (GLS) is a metabolic enzyme. Glutaminase catalyzes the conversion of glutamine to glutamate, which is a key step in glutaminolysis. The glutaminase isoenzymes GLS and GLS2 differ in their expression patterns and functional roles: GLS exhibits oncogenic properties, whereas GLS2 is regarded as a tumor suppressor. Glutaminase expression levels correlate with the degree of tumor malignancy .
loading...
    loading...
Cat. No.: HY-118953
CAS No.: 270902-51-7
Target:  

MetAP Drug Intermediate

Research Areas:  

Cancer

LAF389, a prodrug of LAF153 (HY-183876), is a methionine aminopeptidase (MetAps) inhibitor with an IC50 of 800 nM against MetAp2, and exhibits a maximum inhibition rate of 20% against MetAp1 at 300 nM. LAF389 possesses antiproliferative, antiangiogenic and cytotoxic activities. LAF389 can be used in research related to cancers such as advanced solid tumors .
loading...
    loading...
Cat. No.: HY-175003
CAS No.: 3097367-11-5
Target:  

Proton Pump

Research Areas:  

Cancer

HV1-IN-2 (Compound 14c) is a human voltage-gated proton channel (HV1) inhibitor with an IC50 of 2.14 μM. HV1-IN-2 has a potent anticancer activity with significant antiproliferative effects against THP-1 and MCF-7 cells. HV1-IN-2 can be used for cancers research, such as colorectal tumours, leukaemia, and breast cancer .
loading...
    loading...
Cat. No.: HY-153755
CAS No.: 2923356-52-7
Synonyms: Polθ-IN-7
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

ART6043 (Polθ-IN-7) is an orally active, selective allosteric DNA polymerase θ (Polθ) inhibitor with an IC50 of 1.3 nM. ART6043 blocks microhomology-mediated end joining (MMEJ) by inhibiting the polymerase function of Polθ. ART6043 suppresses the survival of homologous recombination-deficient (HRD) cells and enhances the antitumor effects of PARP inhibitors. ART6043 can be used in studies of HRD tumors, including BRCA1-mutant triple-negative breast cancer, BRCA2-deficient colorectal cancer, RAD51C-deficient gastric cancer, and others .
loading...
    loading...
Cat. No.: HY-117087
CAS No.: 1071544-43-8
Target:  

Phosphatase PANoptosis

Research Areas:  

Cancer

K103 is an inhibitor discovered from the screen that is an analog of the serotonin antagonist benzazocine. K103 exhibited inhibition of SHIP homologues, labelling it a pan-SHIP1/2 inhibitor, but the molecule had no effect on another 5' inositol phosphatase, OCRL. In line with the "two PIPs hypothesis", the molecule exhibited significant anti-tumour effects against a variety of cell lines, particularly breast cancer cells. Additional studies with K103 revealed that inhibition of SHIP1/2 in multiple myeloma cells resulted in G2/M cell cycle arrest followed by extensive apoptosis via activation of the caspase cascade. K103 fits the commonly used small molecule agent property profile, but while this work was being conducted, it was discovered that K103 caused psychoactive effects in mice, which limited the utility of the molecule in vivo. Therefore, certain synthetic studies were conducted on this tryptamine to identify the features that needed to be present in the molecule to maintain pan-SHIP1/2 inhibition in order to design an inhibitor with favourable pharmacodynamic properties and an improved side effect profile.
loading...
    loading...
Cat. No.: HY-144868
CAS No.: 2632968-72-8
Purity:  98.32%
Research Areas:  

Cancer

Glutathione synthesis-IN-1 is an orally active radiosensitizer and intracellular glutathione synthesis inhibitor. Glutathione synthesis-IN-1 can be used in the research of melanoma and glioma .
loading...
    loading...
Cat. No.: HY-112111A
CAS No.: 25513-46-6
Poly-L-Glutamic acid (MW 100000) is a synthetic polypeptide with biocompatibility, biodegradability and non-immunogenicity. Poly-L-Glutamic acid is an ideal tumor-targeting polymer carrier. Poly-L-Glutamic acid can be hydrolyzed by cathepsin B during metabolic decomposition .
loading...
    loading...
Cat. No.: HY-183778
CAS No.: 3091622-60-2
Target:  

VEGFR Caspase Apoptosis

Research Areas:  

Cancer

Antiangiogenic agent 9 is an antiangiogenic agent and also a VEGFR-2 inhibitor. Antiangiogenic agent 9 induces apoptosis of breast cancer cells by activating caspase-3 (apoptosis). Antiangiogenic agent 9 exhibits antiproliferative activity against breast cancer cells. Antiangiogenic agent 9 can be used for the research of breast cancer .
loading...
    loading...
Cat. No.: HY-118713
CAS No.: 133401-10-2
Kuanoniamine A is a pyridoacridine alkaloid and also an anticancer agent. Kuanoniamine A inhibits DNA synthesis, induces apoptosis, and regulates the cell cycle by reducing the proportion of cells in the G2/M phase. Kuanoniamine A inhibits the proliferation of human lymphocytes. Kuanoniamine A can be used in research related to breast cancer, glioma, non-small cell lung cancer, and melanoma .
loading...
    loading...
Cat. No.: HY-N11231
CAS No.: 7176-02-5
Fucoxanthinol, a carotenoid, is a deacetylated Fucoxanthin (HY-N2302) metabolite with oral activity, and inhibits rat pancreatic lipase with an IC50 of 764 nM. Fucoxanthinol reduces expression of Bcl-2, Bcl-xL, survivin, XIAP, cIAP2, cyclin D1, cyclin D2, cyclin E, CDK4, CDK6, β-catenin, JunD, PPARγ, and induces GADD45α expression. Fucoxanthinol activates caspase-3, caspase-8, caspase-9, Nrf2/Keap1/ARE pathway, and inhibits activation of Akt, NF-κB, AP-1, PDPK1, GSK3β phosphorylation. Fucoxanthinol induces apoptosis, G0/G1 cell cycle arrest, inhibits cancer cell viability, proliferation, migration, invasiveness, tumour growth, adipocyte differentiation, oxidative stress, neurotoxicity, triglyceride absorption, angiogenesis, and obesity-induced inflammation. Fucoxanthinol can be used for the research of osteosarcoma, leukemia, lymphoma, adult T-cell leukemia, prostate cancer, colon cancer, breast cancer, hypertriglyceridaemia, Alzheimer’s disease, Parkinson’s disease, obesity, insulin resistance, malignant melanoma, and type II diabetes .
loading...
    loading...
Cat. No.: HY-171718
CAS No.: 550356-40-6
Research Areas:  

Cancer

seco-CBI-PBD dimer is a CBI-PBD heterodimer and a minor groove DNA crosslinker. seco-CBI-PBD dimer exhibits cytotoxicity against human tumor cells at sub-pM to low nM levels, shows low sensitivity to P-glycoprotein-mediated drug resistance, and can serve as an ADC payload. seco-CBI-PBD dimer can be used in studies of uterine cancer, breast cancer, non-small cell lung cancer, etc.
loading...
    loading...
Cat. No.: HY-115425
CAS No.: 23734-88-5
Synonyms: DL-Aminoglutethimide phosphate
Target:  

Cytochrome P450

Aminoglutethimide phosphate (DL-Aminoglutethimide phosphate) is an orally active anticonvulsant with various endocrine-related side effects. Aminoglutethimide phosphate blocks multiple steroid hormone synthesis pathways by inhibiting several cytochrome P-450-dependent hydroxylases, such as aromatase, cholesterol side-chain cleavage enzyme, 11-hydroxylase, and 18-hydroxylase, with IC50 values of 0.3, 3.5, 120, and 20 μM, respectively. Aminoglutethimide phosphate reduces cortisol levels. Aminoglutethimide phosphate can be used in research on Cushing's syndrome, breast cancer, and other conditions .
loading...
    loading...
  • 1